DE602004023971D1 - Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken; verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält - Google Patents
Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken; verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthältInfo
- Publication number
- DE602004023971D1 DE602004023971D1 DE602004023971T DE602004023971T DE602004023971D1 DE 602004023971 D1 DE602004023971 D1 DE 602004023971D1 DE 602004023971 T DE602004023971 T DE 602004023971T DE 602004023971 T DE602004023971 T DE 602004023971T DE 602004023971 D1 DE602004023971 D1 DE 602004023971D1
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- preparation
- pyrroloa2
- büpyridine
- kinaseinhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0330042.3A GB0330042D0 (en) | 2003-12-24 | 2003-12-24 | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
PCT/EP2004/014676 WO2005063747A1 (en) | 2003-12-24 | 2004-12-23 | PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004023971D1 true DE602004023971D1 (de) | 2009-12-17 |
Family
ID=30776534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004023971T Active DE602004023971D1 (de) | 2003-12-24 | 2004-12-23 | Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken; verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält |
Country Status (10)
Country | Link |
---|---|
US (2) | US7888508B2 (de) |
EP (1) | EP1704147B1 (de) |
JP (2) | JP5053643B2 (de) |
AT (1) | ATE447571T1 (de) |
BR (1) | BRPI0418179A (de) |
CA (1) | CA2550686C (de) |
DE (1) | DE602004023971D1 (de) |
ES (1) | ES2333437T3 (de) |
GB (1) | GB0330042D0 (de) |
WO (1) | WO2005063747A1 (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003279230A1 (en) * | 2002-10-09 | 2004-05-04 | Scios Inc. | AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE |
DK1696920T3 (en) | 2003-12-19 | 2015-01-19 | Plexxikon Inc | RELATIONS AND PROCEDURES FOR THE DEVELOPMENT OF LAW MODULATORS |
GB0330042D0 (en) * | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
CN101830899A (zh) | 2004-12-23 | 2010-09-15 | 霍夫曼-拉罗奇有限公司 | 杂环氨基甲酸酯衍生物,它们的制备及作为药剂的应用 |
EP1833829A2 (de) | 2004-12-23 | 2007-09-19 | F. Hoffmann-Roche AG | Benzamidsubstituierte imidazo- und pyrrolopyridine als proteinkinaseinhibitoren |
JP2008545652A (ja) | 2005-05-17 | 2008-12-18 | プレキシコン,インコーポレーテッド | c−kitおよびc−fms活性を調節する化合物およびその用途 |
MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
US7776878B2 (en) | 2005-08-01 | 2010-08-17 | Hoffmann-La Roche Inc. | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
EA200970361A1 (ru) | 2006-10-09 | 2010-02-26 | Такеда Фармасьютикал Компани Лимитед | Ингибиторы киназы |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
RU2009122670A (ru) | 2006-12-21 | 2011-01-27 | Плекссикон, Инк. (Us) | Соединения и способы для модуляции киназ и показания к их применению |
PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
DE602008003055D1 (de) * | 2007-05-31 | 2010-12-02 | Nerviano Medical Sciences Srl | Zyklokondensierte Azaindole, die als Kinase-Hemmer wirken |
MX2010000617A (es) | 2007-07-17 | 2010-05-17 | Plexxikon Inc | Compuestos y metodos para modulacion de cinasa, e indicaciones de estos. |
CL2009001152A1 (es) * | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
FR2941948B1 (fr) * | 2009-02-12 | 2013-04-05 | Nova Decision | Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src |
NZ594398A (en) | 2009-04-03 | 2014-03-28 | Plexxikon Inc | Propane-1-sulfonic acid (3-[5-(4-chloro-phenyl)-1h-pyrrol [2, 3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl} -amide compositions and uses thereof |
ES2432029T3 (es) * | 2009-07-15 | 2013-11-29 | Abbvie Inc. | Inhibidores de quinasas de pirrolopiridina |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
KR20120102669A (ko) | 2009-11-06 | 2012-09-18 | 플렉시콘, 인코퍼레이티드 | 키나제 조정을 위한 화합물 및 방법, 및 이를 위한 적응증 |
EP3521291A1 (de) | 2010-05-20 | 2019-08-07 | Array Biopharma, Inc. | Makrocyclische verbindungen als trk-kinasehemmer |
US9624213B2 (en) | 2011-02-07 | 2017-04-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
CA2969164A1 (en) * | 2014-12-23 | 2016-06-30 | Genfit | Heterocyclic derivatives as rorgamma modulators |
EP3322706B1 (de) | 2015-07-16 | 2020-11-11 | Array Biopharma, Inc. | Substituierte pyrazol[1,5-a]pyridin-verbindungen als ret-kinasehemmer |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
EP3571203B1 (de) | 2017-01-18 | 2023-06-07 | Array BioPharma Inc. | Substituierte pyrazolo[1,5-a]pyrazin verbindungen als ret kinase inhibitoren |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
TWI802635B (zh) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物 |
CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
CA3087578C (en) | 2018-01-18 | 2023-08-08 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3320268A (en) * | 1964-08-14 | 1967-05-16 | Merck & Co Inc | 1-aroyl or heteroaroyl-7-azaindole-3-carboxylates and derivatives |
HUT71553A (en) * | 1992-08-06 | 1995-12-28 | Warner Lambert Co | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
GB9407447D0 (en) | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
GB9412719D0 (en) * | 1994-06-24 | 1994-08-17 | Erba Carlo Spa | Substituted azaindolylidene compounds and process for their preparation |
GB9420521D0 (en) | 1994-10-12 | 1994-11-30 | Smithkline Beecham Plc | Novel compounds |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
WO1998006715A1 (en) * | 1996-08-09 | 1998-02-19 | Smithkline Beecham Corporation | Novel piperazine containing compounds |
HUP0003608A3 (en) | 1997-05-03 | 2001-06-28 | Smithkline Beecham Plc | Tetrahydroisoquinoline derivatives, process for producing them and pharmaceutical compositions containing them |
IL136738A0 (en) | 1997-12-22 | 2001-06-14 | Bayer Ag | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
AUPP150098A0 (en) | 1998-01-27 | 1998-02-19 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
FR2778662B1 (fr) | 1998-05-12 | 2000-06-16 | Adir | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
GB9821977D0 (en) | 1998-10-08 | 1998-12-02 | Smithkline Beecham Plc | Compounds |
MA26696A1 (fr) | 1998-10-08 | 2004-12-20 | Smithkline Beecham Plc | Derives de tetrahydrobenzazepine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant |
GB9821978D0 (en) | 1998-10-08 | 1998-12-02 | Smithkline Beecham Plc | Compounds |
US6492406B1 (en) | 1999-05-21 | 2002-12-10 | Astrazeneca Ab | Pharmaceutically active compounds |
DE60027431T2 (de) | 1999-07-02 | 2007-07-12 | Stuart A. Rancho Santa Fe Lipton | Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten |
US6653304B2 (en) | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
US6476034B2 (en) * | 2000-02-22 | 2002-11-05 | Bristol-Myers Squibb Company | Antiviral azaindole derivatives |
WO2001081345A1 (fr) * | 2000-04-20 | 2001-11-01 | Mitsubishi Pharma Corporation | Composes d'amides aromatiques |
US6335342B1 (en) | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
DE10152306A1 (de) * | 2001-10-26 | 2003-07-24 | Asta Medica Ag | 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften |
FR2836914B1 (fr) * | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
AU2003214412A1 (en) * | 2002-03-28 | 2003-10-13 | Eisai R & D Management Co., Ltd. | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders |
GB0330042D0 (en) * | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
-
2003
- 2003-12-24 GB GBGB0330042.3A patent/GB0330042D0/en not_active Ceased
-
2004
- 2004-12-23 JP JP2006546079A patent/JP5053643B2/ja active Active
- 2004-12-23 ES ES04804268T patent/ES2333437T3/es active Active
- 2004-12-23 EP EP04804268A patent/EP1704147B1/de active Active
- 2004-12-23 BR BRPI0418179-4A patent/BRPI0418179A/pt not_active Application Discontinuation
- 2004-12-23 US US11/020,794 patent/US7888508B2/en active Active
- 2004-12-23 CA CA2550686A patent/CA2550686C/en active Active
- 2004-12-23 WO PCT/EP2004/014676 patent/WO2005063747A1/en active Application Filing
- 2004-12-23 AT AT04804268T patent/ATE447571T1/de not_active IP Right Cessation
- 2004-12-23 DE DE602004023971T patent/DE602004023971D1/de active Active
-
2011
- 2011-02-14 US US13/026,789 patent/US8198298B2/en active Active
-
2012
- 2012-01-20 JP JP2012010439A patent/JP2012121892A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2333437T3 (es) | 2010-02-22 |
JP2007516997A (ja) | 2007-06-28 |
GB0330042D0 (en) | 2004-01-28 |
US7888508B2 (en) | 2011-02-15 |
WO2005063747A1 (en) | 2005-07-14 |
US20050209269A1 (en) | 2005-09-22 |
JP2012121892A (ja) | 2012-06-28 |
BRPI0418179A (pt) | 2007-04-27 |
CA2550686C (en) | 2015-09-15 |
JP5053643B2 (ja) | 2012-10-17 |
CA2550686A1 (en) | 2005-07-14 |
US20110136857A1 (en) | 2011-06-09 |
EP1704147B1 (de) | 2009-11-04 |
EP1704147A1 (de) | 2006-09-27 |
ATE447571T1 (de) | 2009-11-15 |
US8198298B2 (en) | 2012-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004023971D1 (de) | Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken; verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält | |
DE602004025741D1 (de) | Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten | |
ATE353013T1 (de) | Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel | |
DE60238999D1 (de) | Aminoindazolderivate mit kinaseinhibierender wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
CN105473140B (zh) | 在化学疗法期间对正常细胞的瞬时保护 | |
CA2486101A1 (en) | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
MXPA02012164A (es) | Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden. | |
PT1427708E (pt) | Derivados amino-ftalazinona activos como inibidors de cinase, processo para a sua preparação e composições farmacêuticas contendo-os | |
NZ527123A (en) | Oxazolyl-pyrazole derivatives as kinase inhibitors | |
CN105263934B (zh) | 作为bet抑制剂的吡唑并‑吡咯烷‑4‑酮衍生物及其在治疗疾病中的用途 | |
MXPA05009719A (es) | Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden. | |
BRPI0517619A (pt) | entidades quìmicas de imidazo[1,2-a] pirazin-8-ilaminas, suas composições farmacêuticas, uso dos referidos compostos na preparação de medicamento, processo de preparação de medicamento e métodos de utilização dos referidos compostos | |
DE602004014163D1 (de) | Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken | |
CN108699085A (zh) | 皮质抑素类似物及其用途 | |
WO2002070515A3 (en) | Chromane derivatives, process for their preparation and their use as antitumor agents | |
KR20240055788A (ko) | 신규한 ras 억제제 | |
TW200502236A (en) | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | |
NZ765534A (en) | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd | |
NZ765534B2 (en) | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |